3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
10
Stomach Neoplasms
3
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Salivary Gland Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Metastatic HER2-positive Breast Cancer
1
Hemangiosarcoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Adenocarcinoma Of Esophagus
1
Interventions
Paclitaxel
50
Capecitabine
50
Trastuzumab
38
Fulvestrant
31
pembrolizumab
27
Cyclophosphamide
27
Carboplatin
27
Gemcitabine
23
Letrozole
21
palbociclib
19
Docetaxel
19
Lapatinib
18
Bevacizumab
18
exemestane
17
eribulin
15
Everolimus
14
abemaciclib
13
Vinorelbine
13
Nivolumab
13
Magnetic Resonance Spectroscopy
12
Cisplatin
12
Anastrozole
12
trastuzumab deruxtecan
11
Zoledronic Acid
11
Doxorubicin
11
Albumin-Bound Paclitaxel
11
olaparib
10
Tamoxifen
10
Specimen Handling
10
Radiotherapy
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
zanidatamab
×
Breast
×
Clear all
NCT05868226
2025-04-04
PRE-I-SPY-PI
QuantumLeap Healthcare Collaborative
Phase 1
Recruiting
124 enrolled